Myllia Biotechnology

Executive Summary

Myllia Biotechnology, based in Vienna, Austria, is a private functional genomics company founded in 2019. The company has developed a proprietary platform that performs high-throughput functional genomics in advanced cellular models, mapping the impact of thousands of genetic perturbations at single-cell resolution. This approach enables a new paradigm for drug discovery by nominating the most promising targets with unprecedented precision. By integrating CRISPR-based screens with single-cell readouts, Myllia's technology addresses key bottlenecks in target identification, reducing attrition rates in downstream development. The platform is particularly suited for complex diseases where traditional genetics fall short, offering a scalable solution for both biopharma partners and internal programs. With a focus on diagnostics and genetics & genomics, Myllia operates at the intersection of cutting-edge biology and computational analysis. The company's platform has the potential to streamline the drug discovery pipeline, from target nomination to validation, and could be applied across therapeutic areas. As a private entity without disclosed funding details, Myllia is likely positioning itself for strategic partnerships or Series A financing to scale its operations. The company's approach aligns with industry trends toward precision medicine and functional genomics, making it a compelling player in the biotech landscape. While still early-stage, Myllia's technology offers a differentiated value proposition that could attract significant interest from pharmaceutical collaborators seeking to de-risk their discovery efforts.

Upcoming Catalysts (preview)

• Q3 2026Announcement of first pharmaceutical partnership or collaboration60% success
• Q4 2026Publication of key proof-of-concept data in a peer-reviewed journal70% success
• Q2 2026Completion of Series A financing round80% success